Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Singh, Balraj ^a   Shamsnia, Anna ^a,b   Raythatha, Milan R ^a,b   Milligan, Ryan D ^a   Cady, Amanda M ^a,c   Madan, Simran ^a,d   Lucci, Anthony ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BUTYRIC ACID; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACTOLISIB; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; GLUCOSE; GLUTAMINE; ITRACONAZOLE; MERCAPTOPURINE; MESSENGER RNA; PACLITAXEL; PHENETHYL ISOTHIOCYANATE; SALINOMYCIN; SELUMETINIB; THIORIDAZINE; TRANSCRIPTION FACTOR ZEB1; VALPROIC ACID; FTO PROTEIN, HUMAN; PROTEIN; TUMOR MARKER;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER CELL LINE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; DRUG SCREENING; EPITHELIAL MESENCHYMAL TRANSITION; EVOLUTIONARY ADAPTATION; FEMALE; FTO GENE; GENE; GENE AMPLIFICATION; GRHL2 GENE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; TRIPLE NEGATIVE BREAST CANCER; ZEB1 GENE; ADAPTATION; ANIMAL; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; OBESITY; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL CULTURE; WESTERN BLOTTING;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; COMPARATIVE GENOMIC HYBRIDIZATION; DRUG RESISTANCE, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; OBESITY; PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 84953842268     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0109487     Document Type: Article

References (42)

1. Nowell PC (1976) The clonal evolution of tumor cell populations. Science 194: 23-28.
2. Fidler IJ, Kripke ML (1977) Metastasis results from preexisting variant cells within a malignant tumor. Science 197: 893-895.
3. Talmadge JE, Wolman SR, Fidler IJ (1982) Evidence for the clonal origin of spontaneous metastases. Science 217: 361-363.
4. Chambers AF, Groom AC, MacDonald IC (2002) Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer 2: 563-572.
5. Talmadge JE, Fidler IJ (2010) AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res 70: 5649-5669.
6. Cifone MA, Fidler IJ (1980) Correlation of patterns of anchorage-independent growth with in vivo behavior of cells from a murine fibrosarcoma. Proc Natl Acad Sci U S A 77: 1039-1043.
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 100: 3983-3988.
8. Guo L, Fan D, Zhang F, Price JE, Lee JS, et al. (2011) Selection of brain metastasis-initiating breast cancer cells determined by growth on hard agar. Am J Pathol 178: 2357-2366.
9. McKnight SL (2010) On getting there from here. Science 330: 1338-1339.
10. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395-399.
11. The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
12. Zhang Q1, Liu Y, Zhou J, Chen W, Zhang Y, et al. (2007) Wild-type p53 reduces radiation hypermutability in p53-mutated human lymphoblast cells. Mutagenesis. 22: 329-334.
13. Bullock AN, Henckel J, Fersht AR. (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19: 1245-1256.
14. Chao HH, He X, Parker JS, Zhao W, Perou CM (2012) Micro-scale genomic DNA copy number aberrations as another means of mutagenesis in breast cancer. PLoS One. 7: e51719.
15. Barnabas N, Cohen D (2013) Phenotypic and molecular characterization of MCF10DCIS and SUM breast cancer cell lines. Int J Breast Cancer 2013: 872743.
16. Pan Q, Bao LW, Merajver SD (2003) Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFkappaB signaling cascade. Mol Cancer Res 1: 701-706.
17. Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, et al. (2010) Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis 27: 233-240.
18. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, et al. (2013) Uncovering the molecular secrets of inflammatory breast cancer biology: an integrated analysis of three distinct affymetrix gene expression datasets. Clin Cancer Res. 19: 4685-4696.
19. Masuda H, Baggerly KA, Wang Y, Iwamoto T, Brewer T, et al. (2013) Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 15: R112.
20. Singh B, Tai K, Madan S, Raythatha MR, Cady AM, et al. (2012) Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS ONE 7: e36510.
21. Cieply B, Farris J, Denvir J, Ford HL, Frisch SM (2013) Epithelial-mesenchymal transition and tumor suppression are controlled by a reciprocal feedback loop between ZEB1 and Grainyhead-like-2. Cancer Res. 73: 6299-6309.
22. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelialmesenchymal transition generates cells with properties of stem cells. Cell. 133: 704-715.
23. Tam WL1, Weinberg RA (2013). The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 19: 1438-1449.
24. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
25. Gerken T, Girard CA, Tung YC, Webby CJ, Saudek V, et al. (2007) The obesity-Associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase. Science 318: 1469-1472.
26. Gulati P, Cheung MK, Antrobus R, Church CD, Harding HP, et al. (2013) Role for the obesity-related FTO gene in the cellular sensing of amino acids. Proc Natl Acad Sci U S A. 110: 2557-2562.
27. Fredriksson R, Hägglund M, Olszewski PK, Stephansson O, Jacobsson JA, et al. (2008) The obesity gene, FTO, is of ancient origin, up-regulated during food deprivation and expressed in neurons of feeding-related nuclei of the brain. Endocrinology. 149: 2062-2071.
28. Jain R, Strickler HD, Fine E, Sparano JA (2013). Clinical studies examining the impact of obesity on breast cancer risk and prognosis. J. Mammary Gland Biol. Neoplasia 18: 257-266.
29. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, et al. (2013) Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 45: 392-398.
30. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, et al. (2009) Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer. Clin Cancer Res 15: 6639-6648.
31. Raghav KP, Wang W, Liu S, Chavez-MacGregor M, Meng X, et al. (2012) cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin. Cancer Res. 18: 2269-2277.
32. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, et al. (2009) Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138: 645-659.
33. Sachlos E, Risueño RM, Laronde S, Shapovalova Z, Lee JH, et al. (2012) Identification of drugs including a dopamine receptor antagonist that selectively target cancer stem cells. Cell 149: 1284-1297.
34. Trachootham D, Zhou Y, Zhang H, Demizu Y, Chen Z, et al. (2006) Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell 10: 241-252.
35. Rudin CM, Brahmer JR, Juergens RA, Hann CL, Ettinger DS, et al. (2013) Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J. Thorac. Oncol. 8: 619-623.
36. Kim J, Tang JY, Gong R, Kim J, Lee JJ, et al. (2010) Itraconazole, a commonly used antifungal that inhibits Hedgehog pathway activity and cancer growth. Cancer Cell 17: 388-399.
37. Xu WS, Parmigiani RB, Marks PA (2007) Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 26: 5541-5552.
38. Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, et al. (2013) Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152: 714-726.
39. Wang Y, Waters J, Leung ML, Unruh A, Roh W, et al. (2014) Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature Jul 30 doi: 10.1038/nature13600. [Epub ahead of print].
40. Berulava T, Ziehe M, Klein-Hitpass L, Mladenov E, Thomale J, et al. (2013) FTO levels affect RNA modification and the transcriptome. Eur J Hum Genet. 21: 317-323.
41. Reid MA, Wang WI, Rosales KR, Welliver MX, Pan M, et al. (2013) The B55a subunit of PP2A drives a p53-dependent metabolic adaptation to glutamine deprivation. Mol Cell 50: 200-211.
42. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, et al. (2007) COX-2 involvement in breast cancer metastasis to bone. Oncogene 26: 3789-3796.